文献速递消化系统肿瘤

早期胰腺癌患者循环外泌体来源DNA中突变KRAS高检出率

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
PubMed 文献 · Ann Oncol · 2017-01-01

比较外泌体DNA(exoDNA)与游离DNA(cfDNA)在胰腺导管腺癌(PDAC)液体活检中的KRAS突变检出。发现队列142例(68例PDAC、20例局限期术后、54例年龄匹配健康对照)及验证队列121例(39例癌症、82例健康对照)。exoDNA在局限期PDAC检出率高于cfDNA,但健康对照亦有相当比例检出突变KRAS。

要点

  • exoDNA在局限期PDAC患者中KRAS突变检出率为66.7%,高于cfDNA的45.5%。
  • 健康对照中exoDNA突变KRAS检出率为7.4%,cfDNA为14.8%。
  • 验证队列早期PDAC患者exoDNA突变KRAS检出率为43.6%,健康对照为20%。

核心结论

  • 外泌体是肿瘤DNA的独特来源,可能与其他液体活检DNA来源互补。
  • 局限期PDAC患者exoDNA中可检测到KRAS突变的比例高于既往报道的cfDNA。
  • 相当比例健康样本循环中可检出突变KRAS,应用液体活检发现需谨慎考虑。

研究设计与样本

  • 研究样本采集于2003年至2010年,临床随访至2015年。
  • 采用微滴数字PCR检测exoDNA和cfDNA中密码子12/13的KRAS突变。
  • 发现队列142例:68例各期PDAC患者、20例初诊局限期且根治性切除后采血的PDAC患者、54例年龄匹配健康对照。
  • 验证队列121例:39例癌症患者和82例健康对照。
  • 主要结局为微滴数字PCR检测的循环KRAS状态,次要结局为无病生存和总生存。

主要发现

  • exoDNA中KRAS突变在年龄匹配对照、局限期、局部晚期和转移性PDAC患者中检出率分别为7.4%、66.7%、80%和85%。
  • cfDNA中突变KRAS在上述人群检出率分别为14.8%、45.5%、30.8%和57.9%。
  • 局限期疾病患者中较高的exoKRAS MAF与无病生存期缩短相关。
  • 验证队列中,早期PDAC患者exoDNA突变KRAS检出率为43.6%,健康对照为20%。

关键数值与推荐

  • exoDNA在局限期PDAC的KRAS突变检出率为66.7%,cfDNA为45.5%。
  • 验证队列早期PDAC患者exoDNA突变KRAS检出率为43.6%。
  • 健康对照中exoDNA突变KRAS检出率为7.4%,cfDNA为14.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 相当比例健康样本循环中可检出突变KRAS,可能限制液体活检作为广泛癌症筛查方法的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived DNA (exoDNA) to cfDNA in liquid biopsies of patients with pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patient samples were obtained between 2003 and 2010, with clinically annotated follow up to 2015. Droplet digital PCR was performed on exoDNA and cfDNA for sensitive detection of KRAS mutants at codons 12/13. A cumulative series of 263 individuals were studied, including a discovery cohort of 142 individuals: 68 PDAC patients of all stages; 20 PDAC patients initially staged with localized disease, with blood drawn after resection for curative intent; and 54 age-matched healthy controls. A validation cohort of 121 individuals (39 cancer patients and 82 healthy controls) was studied to validate KRAS detection rates in early-stage PDAC patients. Primary outcome was circulating KRAS status as detected by droplet digital PCR. Secondary outcomes were disease-free and overall survival. RESULTS: KRAS mutations in exoDNA, were identified in 7.4%, 66.7%, 80%, and 85% of age-matched controls, localized, locally advanced, and metastatic PDAC patients, respectively. Comparatively, mutant KRAS cfDNA was detected in 14.8%, 45.5%, 30.8%, and 57.9% of these individuals. Higher exoKRAS MAFs were associated with decreased disease-free survival in patients with localized disease. In the validation cohort, mutant KRAS exoDNA was detected in 43.6% of early-stage PDAC patients and 20% of healthy controls. CONCLUSIONS: Exosomes are a distinct source of tumor DNA that may be complementary to other liquid biopsy DNA sources. A higher percentage of patients with localized PDAC exhibited detectable KRAS mutations in exoDNA than previously reported for cfDNA. A substantial minority of healthy samples demonstrated mutant KRAS in circulation, dictating careful consideration and application of liquid biopsy findings, which may limit its utility as a broad cancer-screening method.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017. PMID: 28104621. doi:10.1093/annonc/mdx004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。